Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 114

1.

ARGX-110, a highly potent antibody targeting CD70, eliminates tumors via both enhanced ADCC and immune checkpoint blockade.

Silence K, Dreier T, Moshir M, Ulrichts P, Gabriels SM, Saunders M, Wajant H, Brouckaert P, Huyghe L, Van Hauwermeiren T, Thibault A, De Haard HJ.

MAbs. 2014 Mar-Apr;6(2):523-32. doi: 10.4161/mabs.27398. Epub 2013 Dec 6.

2.

Unlocking the potential of CD70 as a novel immunotherapeutic target for non-small cell lung cancer.

Jacobs J, Zwaenepoel K, Rolfo C, Van den Bossche J, Deben C, Silence K, Hermans C, Smits E, Van Schil P, Lardon F, Deschoolmeester V, Pauwels P.

Oncotarget. 2015 May 30;6(15):13462-75.

3.

Preclinical characterization of SGN-70, a humanized antibody directed against CD70.

McEarchern JA, Smith LM, McDonagh CF, Klussman K, Gordon KA, Morris-Tilden CA, Duniho S, Ryan M, Boursalian TE, Carter PJ, Grewal IS, Law CL.

Clin Cancer Res. 2008 Dec 1;14(23):7763-72. doi: 10.1158/1078-0432.CCR-08-0493.

4.

CD70 reverse signaling enhances NK cell function and immunosurveillance in CD27-expressing B-cell malignancies.

Al Sayed MF, Ruckstuhl CA, Hilmenyuk T, Claus C, Bourquin JP, Bornhauser BC, Radpour R, Riether C, Ochsenbein AF.

Blood. 2017 Jul 20;130(3):297-309. doi: 10.1182/blood-2016-12-756585. Epub 2017 May 11.

PMID:
28495792
5.

Engineered anti-CD70 antibody with multiple effector functions exhibits in vitro and in vivo antitumor activities.

McEarchern JA, Oflazoglu E, Francisco L, McDonagh CF, Gordon KA, Stone I, Klussman K, Turcott E, van Rooijen N, Carter P, Grewal IS, Wahl AF, Law CL.

Blood. 2007 Feb 1;109(3):1185-92. Epub 2006 Oct 12.

6.

Depleting MET-Expressing Tumor Cells by ADCC Provides a Therapeutic Advantage over Inhibiting HGF/MET Signaling.

Hultberg A, Morello V, Huyghe L, De Jonge N, Blanchetot C, Hanssens V, De Boeck G, Silence K, Festjens E, Heukers R, Roux B, Lamballe F, Ginestier C, Charafe-Jauffret E, Maina F, Brouckaert P, Saunders M, Thibault A, Dreier T, de Haard H, Michieli P.

Cancer Res. 2015 Aug 15;75(16):3373-83. doi: 10.1158/0008-5472.CAN-15-0356. Epub 2015 Jul 3.

7.

Phase 1 dose-escalation study of the anti-CD70 antibody ARGX-110 in Advanced Malignancies.

Aftimos P, Rolfo C, Rottey S, Offner F, Bron DD, Maerevoet M, Soria JC, Moshir M, Dreier T, van Rompaey L, Michot JM, Silence K, Hultberg A, Gandini D, De Haard H, Ribrag V, Peeters M, Thibault A, Leupin N, Awada A.

Clin Cancer Res. 2017 Aug 1. pii: clincanres.0613.2017. doi: 10.1158/1078-0432.CCR-17-0613. [Epub ahead of print]

PMID:
28765328
8.

Agonist anti-human CD27 monoclonal antibody induces T cell activation and tumor immunity in human CD27-transgenic mice.

He LZ, Prostak N, Thomas LJ, Vitale L, Weidlick J, Crocker A, Pilsmaker CD, Round SM, Tutt A, Glennie MJ, Marsh H, Keler T.

J Immunol. 2013 Oct 15;191(8):4174-83. doi: 10.4049/jimmunol.1300409. Epub 2013 Sep 11.

9.

Blockade of CD70-CD27 interaction inhibits induction of allergic lung inflammation in mice.

Makino F, Ito J, Abe Y, Harada N, Kamachi F, Yagita H, Takahashi K, Okumura K, Akiba H.

Am J Respir Cell Mol Biol. 2012 Sep;47(3):298-305. doi: 10.1165/rcmb.2011-0354OC. Epub 2012 Apr 12.

PMID:
22499851
10.

CD27-CD70 interactions regulate B-cell activation by T cells.

Kobata T, Jacquot S, Kozlowski S, Agematsu K, Schlossman SF, Morimoto C.

Proc Natl Acad Sci U S A. 1995 Nov 21;92(24):11249-53.

11.

T cells redirected against CD70 for the immunotherapy of CD70-positive malignancies.

Shaffer DR, Savoldo B, Yi Z, Chow KK, Kakarla S, Spencer DM, Dotti G, Wu MF, Liu H, Kenney S, Gottschalk S.

Blood. 2011 Apr 21;117(16):4304-14. doi: 10.1182/blood-2010-04-278218. Epub 2011 Feb 8.

12.

Targeting the T-cell co-stimulatory CD27/CD70 pathway in cancer immunotherapy: rationale and potential.

van de Ven K, Borst J.

Immunotherapy. 2015;7(6):655-67. doi: 10.2217/imt.15.32. Epub 2015 Jun 22. Review.

13.

Targeting CD70 for human therapeutic use.

Boursalian TE, McEarchern JA, Law CL, Grewal IS.

Adv Exp Med Biol. 2009;647:108-19. doi: 10.1007/978-0-387-89520-8_7. Review.

PMID:
19760069
14.

CD70: An emerging target in cancer immunotherapy.

Jacobs J, Deschoolmeester V, Zwaenepoel K, Rolfo C, Silence K, Rottey S, Lardon F, Smits E, Pauwels P.

Pharmacol Ther. 2015 Nov;155:1-10. doi: 10.1016/j.pharmthera.2015.07.007. Epub 2015 Jul 26. Review.

PMID:
26213107
15.

Therapeutic targeting of CD70 and CD27.

Wajant H.

Expert Opin Ther Targets. 2016 Aug;20(8):959-73. doi: 10.1517/14728222.2016.1158812. Epub 2016 Mar 15. Review.

PMID:
26914723
16.

Signaling through CD70 regulates B cell activation and IgG production.

Arens R, Nolte MA, Tesselaar K, Heemskerk B, Reedquist KA, van Lier RA, van Oers MH.

J Immunol. 2004 Sep 15;173(6):3901-8.

17.

Blocking CD27-CD70 costimulatory pathway suppresses experimental colitis.

Manocha M, Rietdijk S, Laouar A, Liao G, Bhan A, Borst J, Terhorst C, Manjunath N.

J Immunol. 2009 Jul 1;183(1):270-6. doi: 10.4049/jimmunol.0802424. Epub 2009 Jun 12. Erratum in: J Immunol. 2009 Sep 15;183(6):4135. Svend, Rietdijk [corrected to Rietdijk, Svend]; Borst, Jannine [corrected to Borst, Jannie].

18.

CD70-restricted specific activation of TRAILR1 or TRAILR2 using scFv-targeted TRAIL mutants.

Trebing J, El-Mesery M, Schäfer V, Weisenberger D, Siegmund D, Silence K, Wajant H.

Cell Death Dis. 2014 Jan 30;5:e1035. doi: 10.1038/cddis.2013.555.

19.

CD27/CD70 interaction directly drives B cell IgG and IgM synthesis.

Agematsu K, Kobata T, Yang FC, Nakazawa T, Fukushima K, Kitahara M, Mori T, Sugita K, Morimoto C, Komiyama A.

Eur J Immunol. 1995 Oct;25(10):2825-9.

PMID:
7589078
20.

CD70-CD27 interactions provide survival and proliferative signals that regulate T cell receptor-driven activation of human γδ peripheral blood lymphocytes.

DeBarros A, Chaves-Ferreira M, d'Orey F, Ribot JC, Silva-Santos B.

Eur J Immunol. 2011 Jan;41(1):195-201. doi: 10.1002/eji.201040905. Epub 2010 Dec 3.

Supplemental Content

Support Center